Clinical trials: sponsored by Fujian Cancer Hospital
Cancer Pain
Using Mini Program for Self-management VS Conventional Pharmaceutical Care for Cancer Pain
With the existing medical system and insufficient medical resources in China, we developed a mini program. a pain management mini app can be useful and appreciated by patients and health care professionals, making it a good…
- Trial name
- NCT04844645
- Testing
- mini program, conventional pharmaceutical care
- Volunteers
- 200 people
- Sponsor
- Fujian Cancer Hospital
Colorectal Adenocarcinoma
Bevacizumab Plus Capecitabin vs S-1 as Maintenance Treatment Following First-line Chemotherapy in the Patients With Advanced Colorectal Adenocarcinoma
Bevacizumab plus capecitabin is a standard maintenance treatment following first-line chemotherapy in the patients with advanced colorectal adenocarcinoma.
- Trial name
- NCT03708536
- Testing
- S-1, Bevacizumab, Capecitabine
- Where
- China
- Sponsor
- Fujian Cancer Hospital
Cancer Pain
PCA vs Non-PCA Intravenous Hydromorphone Titration for Severe Cancer Pain
A large number of studies have shown that patients feel more satisfied with hydromorphone in the pain management. and a systematic review found that hydromorphone may be better suited than morphine for titration of acute…
- Trial name
- NCT03375515
- Testing
- Hydromorphone, PCA pump
- Where
- China
- Volunteers
- 214 people
- Sponsor
- Fujian Cancer Hospital
Metastatic Colorectal Cancer
Phase I Study of Biweekly SIRB Regimen for Metastatic Colorectal Cancer
Phase I Study of biweekly combination therapy with S-1, Irinotecan, and Bevacizumab as 1-line Chemotherapy in Patients With Advanced Colorectal Cancer.
- Trial name
- SIRB2 (NCT03380689)
- Testing
- S-1, Irinotecan, Bevacizumab
- Where
- China
- Sponsor
- Fujian Cancer Hospital
Cancer Pains
Change the Dose Frequency of Controlled-Release Oxycodone to Refractory Pain
Many patients with cancer experience moderate to severe pain that requires treatment with strong opioids, of which oxycodone and morphine are examples, they are widely applied in clinical treatment because of sustained-released…
- Trial name
- NCT03639415
- Testing
- Increasing the Controlled-Release Oxycodone dose frequency
- Volunteers
- healthy volunteers welcome
- Sponsor
- Fujian Cancer Hospital
Cancer Pain
Intravenous vs Oral Analgesia in Cancer Patients With Severe Pain After Successful Titration
Pain is one of the most common and fear symptoms for cancer patients, which seriously affects the quality of life in cancer patients. At present, oral opioid is the most common route to administrate cancer pain.
- Trial name
- NCT04243954
- Testing
- PCA IV Hydromorphone (continuous dose = 0), PCA IV Hydromorphone (continuous dose ≠ 0), Oral morphine
- Where
- China
- Volunteers
- 95 people
- Sponsor
- Fujian Cancer Hospital
Advanced Colorectal Cancer
Second-line Surufatinib Combined With Chemotherapy in Advanced CRC
A phase II, muti-cohort study to assess the efficacy and safety of Surufatinib combined with chemotherapy as a second-line treatment in patients with advanced CRC
- Trial name
- NCT04734249
- Testing
- Surufatinib(HMPL-012)
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Fujian Cancer Hospital
NSCLC Stage IV
Toripalimab as Maintenance Therapy in Patients With Driver-gene Negative Advanced NSCLC After First-line Chemotherapy
Lung cancer is the malignant tumor with the highest incidence and mortality in China. Non-small cell lung cancer (NSCLC) ,which includes non-squamous cell carcinoma (including adenocarcinoma, large cell carcinoma, and other cell…
- Trial name
- NCT04613804
- Testing
- Toripalimab Injection
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Fujian Cancer Hospital
Nasopharyngeal Carcinoma
To Evaluate the Efficacy and Feasibility of Modified Reduce-volume Target IMRT in the Treatment of Patients With Non-metastatic NPC
This is a retrospective real-world study to evaluate the efficacy and feasibility of modified reduce-volume target IMRT in the treatment of patients with non-metastatic NPC
- Trial name
- NCT04387266
- Testing
- modified reduce-volume target IMRT
- Where
- China
- Volunteers
- 471 people
- Sponsor
- Fujian Cancer Hospital
Opioid, Moderate Cancer Pain, Transdermal Fentanyl, 12.5ug/h, Opioid-naive
Opioid Titration With 12.5 ug/h Fentanyl Transdermal Patch vs Orally Morphine for Opioid-naïve Patients With Moderate Cancer Pain
Opioid is recommended for moderate cancer pain in WHO 3-step analgesic ladder. Transdermal administration of the strong opioid fentanyl was originally developed for patients unable to swallow analgesics because of malignancies in…
- Trial name
- NCT04533243
- Testing
- 2.5ug/h transdermal fentanyl, Oral immediate-released morphine
- Volunteers
- 209 people
- Sponsor
- Fujian Cancer Hospital
Nasopharyngeal Carcinoma
EBV-TCR-T（YT-E001）for Patients With EBV-positive Recurrent or Metastatic NPC
TCR-T cell therapy experienced a breakthrough for treating tumors in recent years. Phase I / II trial of NY-ESO-1-specific TCR-T treatment for synovial sarcoma and melanoma conducted by the Rosenberg team at the National Cancer…
- Trial name
- NCT03648697
- Testing
- EBV-TCR-T (YT-E001) cells
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Fujian Cancer Hospital
Nasopharyngeal Carcinoma
Triprilimab(JS001) and Chemotherapy Combined With Local Treatment for Multiple Metastatic NPC
This study is a randomized, phase II, prospective, multicenter clinical trial to evaluate the efficacy and tolerability of JS001 and chemotherapy combined with local treatment in patients with multiple metastatic nasopharyngeal…
- Trial name
- NCT04421469
- Testing
- Triprilimab(JS001)
- Where
- China
- Volunteers
- 39 people
- Sponsor
- Fujian Cancer Hospital
Nasopharyngeal Carcinoma
Sufficient Chemotherapy Combine With Maintenance Chemotherapy in the Treatment of Oligometastatic Nasopharyngeal Carcinoma
This study is a randomized, phase II, prospective, multicenter clinical trial to evaluate the efficacy and safety of sufficient chemoradiotherapy plus oral capecitabine/S-1 for 1 year in the treatment of oligometastatic…
- Trial name
- NCT04319471
- Testing
- Capecitabine/S-1, Chemotherapy, Head and neck radiotherapy
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Fujian Cancer Hospital
Nasopharyngeal Carcinoma
Radical Radiotherapy and Chemotherapy Combined With Maintenance Chemotherapy in the Treatment of Stage N3 NPC
This study is a randomized, phase II, prospective, multicenter clinical trial to evaluate the efficacy and safety of radical chemoradiotherapy plus oral capecitabine/teggio for 1 year in patients with N3.
- Trial name
- NCT04220528
- Testing
- Capecitabine/Tiggio
- Where
- China
- Volunteers
- 129 people
- Sponsor
- Fujian Cancer Hospital
Advanced Gastric Adenocarcinoma
PD-1 Antibody(SHR-1210) Plus Apatinib Combined With POF in Advanced Gastric Cancer
This study is a single center, phase II study, to evaluate the effectiveness and safety of PD-1 Antibody(SHR-1210) Plus apatinib Combined With POF(paclitaxel plus oxaliplatin plus 5-fluorouracil plus leucovorin) , in the…
- Trial name
- NCT04174339
- Testing
- Camrelizumab, Apatinib Mesylate, POF
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Fujian Cancer Hospital
Gastric Cancer
POF Versus FOLFOX Plus IP Paclitaxel in AGC
The aim of this study was to compare the efficacy and safety of intravenous or intraperitoneal paclitaxel plus FOLFOX as first-line treatment in AGC with peritoneal metastases, a phase II Clinical trial.
- Trial name
- NCT04155671
- Testing
- POF, FOLFOX plus PAC(ip)
- Volunteers
- 260 people
- Sponsor
- Fujian Cancer Hospital
Gastric Cancer
Neoadjuvant POF in the Treatment of Locally Advanced Gastric Cancer
This study is a single center, phase II study, to evaluate the effectiveness and safety of POF(paclitaxel plus oxaliplatin plus 5-fluorouracil plus leucovorin) , in the neoadjuvant therapy for patients with advanced/metastatic…
- Trial name
- NCT04149015
- Testing
- paclitaxel ,oxaliplatin,fluorouracil
- Volunteers
- 20 people
- Sponsor
- Fujian Cancer Hospital
Gastric Cancer Stage III
A Randomized Phase III Study Comparing POF With SOX/CAPOX/FOLFOX as a Postoperative Adjuvant Chemotherapy for Curatively Resected Stage III Gastric Cancer
FNF-014 is a randomised, open-label, multicentre, parallel-group, phase 3 study in China to prove superiority of POF over S-1/docetaxel in postoperative adjuvant setting for pStage III gastric adenocarcinoma (including…
- Trial name
- NCT03788226
- Testing
- POF, CAPOX/SOX/FOLFOX
- Where
- China
- Volunteers
- 600 people
- Sponsor
- Fujian Cancer Hospital
Gastric Adenocarcinoma, Advanced Cancer
Study of the Apatinib Combine With POF Versus POF in Gastric Cancer
This study is a randomized, parallel control, multicenter,phase II study, comparing the efficacy and safety of apatinib plus POF(paclitaxel plus oxaliplatin plus 5-fluorouracil plus leucovorin) versus POF, in the first-line…
- Trial name
- NCT04121039
- Testing
- Apatinib, POF
- Where
- China
- Volunteers
- 116 people
- Sponsor
- Fujian Cancer Hospital
Advanced Metastatic Gastric Cancer
Apatinib Plus Sintilimab in Advanced Gastric Cancer Refractory to at Least Two Previous Chemotherapy Regimens
The purpose of this study is to assess the efficacy and safety of Apatinib combined with PD-1 antibody Sintilimab for for Chemotherapy-Refractory Advanced Metastatic Gastric Cancer
- Trial name
- ASGARD (NCT04089657)
- Testing
- Apatinib Mesylate, Sintilimab
- Volunteers
- 40 people
- Sponsor
- Fujian Cancer Hospital